Natco Pharma launches two new cancer treatment tablets in India and US markets

Both these tablets are antineoplastic drugs used in the treatment of certain types of cancers.

Natco Pharma Ltd, a multinational pharmaceutical company headquartered in Hyderabad, announced today the launch of Tipanat tablets, a novel antineoplastic nucleoside analogue used in the treatment of advanced colorectal and gastric cancer, which affects approximately 1,25,000 people every year in India.

The Tipanat tablet is a brand new fixed-dose combination of Trifluridine and Tipiracil, that has been launched for the first time in India. Owing to its usefulness in extending survival as well as preserving the quality of life in the late lines of treatment, Tipanat is a very significant launch.

Moreover, in collaboration with its marketing partner Breckenridge Pharmaceutical Inc., the company also announced the launch of Everolimus Tablet, an antineoplastic chemotherapy drug in the US markets. These tablets are available in the 10 mg strength and are a generic version of Afinitor.

On the addressable market front, as per the industry sales statistics, in 1 year ending July 2021, Afinitor tablets of 10 mg strength generated annual sales of USD 392 million. Before the launch of Everolimus Tablets in 10 mg strength, Natco Pharma, along with Breckenridge Pharmaceutical Inc., had also launched the same tablet in 2.5mg, 5mg and 7.5mg strengths during the first quarter of 2021 in the US markets.

Talking about the company’s financials, in the recent quarter Q2 FY22, on a consolidated basis, the net sales stood at Rs 377.20. The PBIDT (ex OI) came in at Rs 70.5 crore, whereas its corresponding margin stood at 18.69%. Lastly, the company’s net profit came in at Rs 65.10 crore, and its corresponding margin stood at 17.26%.

At the closing bell on Thursday, the stock price of Natco Pharma Ltd was trading at Rs 814.65, a decline of 0.81% from the previous day’s closing price of Rs 821.30 on BSE.